Benzinga | Oct 28, 2021 06:58AM EDT

Sanofi Raises FY21 Earnings Outlook As Dupixent, Vaccines Boost Q3 Performance

* Sanofi SA's (NASDAQ:SNY) Q3 sales grew 10.1% Y/Y to (euro)10.4 billion due to solid growth from Dupixent, Vaccines, and Consumer Healthcare.

* EPS for the quarter increased 19.1% on reported and CER basis to (euro)2.18.

* Sales from eczema treatment, Dupixent, jumped 54% to (euro)1.41 billion.

* Vaccines sales increased 16.5% to (euro)2.42 billion with record quarterly sales driven by flu vaccines and meningitis franchise recovery.

* Consumer Healthcare sales increased 11.1% to (euro)1.16 billion, driven by the growth of Pain care and Digestive Wellness categories.

* The gross margin increased 1.9 percentage points to 72.8% versus the third quarter of 2020.

* Sanofi generated a free cash flow of (euro)2.20 billion.

* Guidance: Sanofi now expects EPS to climb by around 14% at constant currencies for FY21, up from a previous, already improved estimate for 12% growth released in July.

* Read Next: Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism.

* Price Action: SNY shares traded higher by 0.69% at $49.91 premarket on the last check Thursday.